These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 24188746)
1. Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan. Lee SU; Kim DY; Kim SY; Baek JY; Chang HJ; Kim MJ; Kim TH; Park JW; Oh JH Radiat Oncol; 2013 Nov; 8():258. PubMed ID: 24188746 [TBL] [Abstract][Full Text] [Related]
2. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Kim DY; Jung KH; Kim TH; Kim DW; Chang HJ; Jeong JY; Kim YH; Son SH; Yun T; Hong CW; Sohn DK; Lim SB; Choi HS; Jeong SY; Park JG Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):378-84. PubMed ID: 17097835 [TBL] [Abstract][Full Text] [Related]
3. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study. Hong YS; Kim DY; Lim SB; Choi HS; Jeong SY; Jeong JY; Sohn DK; Kim DH; Chang HJ; Park JG; Jung KH Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1171-8. PubMed ID: 20605355 [TBL] [Abstract][Full Text] [Related]
4. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer. Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482 [TBL] [Abstract][Full Text] [Related]
5. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. Gollins S; Sun Myint A; Haylock B; Wise M; Saunders M; Neupane R; Essapen S; Samuel L; Dougal M; Lloyd A; Morris J; Topham C; Susnerwala S J Clin Oncol; 2011 Mar; 29(8):1042-9. PubMed ID: 21263095 [TBL] [Abstract][Full Text] [Related]
6. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070 [TBL] [Abstract][Full Text] [Related]
7. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Willeke F; Horisberger K; Kraus-Tiefenbacher U; Wenz F; Leitner A; Hochhaus A; Grobholz R; Willer A; Kähler G; Post S; Hofheinz RD Br J Cancer; 2007 Mar; 96(6):912-7. PubMed ID: 17325705 [TBL] [Abstract][Full Text] [Related]
9. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study. Kim SY; Hong YS; Kim DY; Kim TW; Kim JH; Im SA; Lee KS; Yun T; Jeong SY; Choi HS; Lim SB; Chang HJ; Jung KH Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):677-83. PubMed ID: 20888703 [TBL] [Abstract][Full Text] [Related]
10. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Chiorean EG; Sanghani S; Schiel MA; Yu M; Burns M; Tong Y; Hinkle DT; Coleman N; Robb B; LeBlanc J; Clark R; Bufill J; Curie C; Loehrer PJ; Cardenes H Cancer Chemother Pharmacol; 2012 Jul; 70(1):25-32. PubMed ID: 22610353 [TBL] [Abstract][Full Text] [Related]
11. Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer. Yeo SG; Kim DY; Park JW; Oh JH; Kim SY; Chang HJ; Kim TH; Kim BC; Sohn DK; Kim MJ Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e193-9. PubMed ID: 21605941 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients. Ugidos L; Delgado S; Conill C; Ginés A; Gallego R; Ayuso JR; Miquel R; Tosca M; de Lacy A; Castells A; Maurel J Invest New Drugs; 2009 Jun; 27(3):262-8. PubMed ID: 18923810 [TBL] [Abstract][Full Text] [Related]
13. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2). Gollins SW; Myint S; Susnerwala S; Haylock B; Wise M; Topham C; Samuel L; Swindell R; Morris J; Mason L; Levine E Br J Cancer; 2009 Sep; 101(6):924-34. PubMed ID: 19690550 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Hofheinz RD; Horisberger K; Woernle C; Wenz F; Kraus-Tiefenbacher U; Kähler G; Dinter D; Grobholz R; Heeger S; Post S; Hochhaus A; Willeke F Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1384-90. PubMed ID: 16979839 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. Park JH; Yoon SM; Yu CS; Kim JH; Kim TW; Kim JC Cancer; 2011 Aug; 117(16):3703-12. PubMed ID: 21328328 [TBL] [Abstract][Full Text] [Related]
16. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174 [TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032 [TBL] [Abstract][Full Text] [Related]
18. Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02. Lee JH; Jang HS; Kim JG; Lee MA; Kim DY; Kim TH; Oh JH; Park SC; Kim SY; Baek JY; Park HC; Kim HC; Nam TK; Chie EK; Jung JH; Oh ST Radiother Oncol; 2014 Oct; 113(1):18-23. PubMed ID: 25245559 [TBL] [Abstract][Full Text] [Related]
19. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Nogué M; Salud A; Vicente P; Arriví A; Roca JM; Losa F; Ponce J; Safont MJ; Guasch I; Moreno I; Ruiz A; Pericay C; Oncologist; 2011; 16(5):614-20. PubMed ID: 21467148 [TBL] [Abstract][Full Text] [Related]
20. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. O'Connell MJ; Colangelo LH; Beart RW; Petrelli NJ; Allegra CJ; Sharif S; Pitot HC; Shields AF; Landry JC; Ryan DP; Parda DS; Mohiuddin M; Arora A; Evans LS; Bahary N; Soori GS; Eakle J; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Wozniak TF; Roh MS; Yothers G; Wolmark N J Clin Oncol; 2014 Jun; 32(18):1927-34. PubMed ID: 24799484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]